Navigating the Crisis of Multidrug-Resistant Infections in Infants to Teenagers: Regional Variability and Global Solutions

Share

Abstract

Superbacteria, or multidrug-resistant (MDR) microorganisms, pose a major global health threat, especially in regions like South Asia and sub-Saharan Africa. Bacteria such as Klebsiella pneumoniae, E. coli, and Pseudomonas aeruginosa are resistant to multiple antibiotics, making infections harder to treat. These resistant infections cause millions of deaths annually, with vulnerable groups like neonates and children being particularly at risk. Overuse of antibiotics in medicine and livestock, along with weak healthcare systems, accelerates the spread of resistance, especially in countries like India, China, and Pakistan. Common resistant infections include urinary tract infections, neonatal sepsis, and ventilator-associated pneumonia. Resistance to antibiotics like carbapenems and third-generation cephalosporins, along with the rise of ESBL-producing bacteria, complicates treatment, particularly in neonatal intensive care units (NICUs). This paper reviews global data on superbacteria, focusing on neonatal and pediatric populations, highlighting the need for better diagnostics, novel treatments (e.g., phage therapy), antimicrobial stewardship, infection control, and global cooperation to combat the growing threat of resistance.